Using Human Cancer Cell Lines as In vitro Model for Testing the Efficacy of CDBPA; a New Anticancer Drug
- *Corresponding Author:
- Fuad Fares
Department of Human Biology, Faculty of Natural Sciences
University of Haifa, Haifa, Israel
E-mail: [email protected]
Received date: April 03, 2016; Accepted date: May 04, 2016; Published date: May 11, 2016
Citation: Fares F, Jensen CL, Larsen S, Azzam N, Fares B, et al. (2016) Using Human Cancer Cell Lines as in vivo Model for Testing the Efficacy of CDBPA; a New Anticancer Drug. J Tissue Sci Eng 7:168. doi:10.4172/2157-7552.1000168
Copyright: © 2016 Fares F, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The aim of the present study was to test the efficacy of cis-coordinated complexes of platinum (II) with the polymer of benzene-poly-carboxylic acids derived from lignin (CDBPA) (laboratory code BP-C1), an innovative anticancer compound, on the growth of several solid human cancer cell lines: bladder cancer, chondrosarcoma, colonic cancer, head and neck cancer, hepatic cancer, ovary cancer, pancreatic cancer and prostatic cancer. Furthermore, the effect of CDBPA on non-Hodgkin lymphoma cell lines was also tested. The effect of CDBPA on cell viability was detected by XTT assay and toxicity was detected by measuring the leakage of Lactate dehydrogenase from the cells to the media. The present study has demonstrated that CDBPA is not toxic and able to reduce cell viability substantially and significantly in various human cancer cell lines. When comparison of viability in percentage of the controls at the maximum given dose of CDBPA for each type of cancer cell line, it was found that the largest impact on the viability was on sarcoma, and then decreases via breast, prostatic, head and neck-, pancreatic, colonic cancer and finally ovarian cancer. In addition, the effect of CDBPA on non-Hodgkin lymphoma cell lines was similar to that found in sarcoma cells. We conclude that the effect of CDBPA on cell viability is different and may be dependent on genotype of the cancer cell type. This may indicate different mechanisms of action in the different cancer types. The results obtained from the in vitro studies are important for designing future in vivo studies using animal models and to predict the clinical outcome in human cancer.